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Summary An oestrogen-sensitive rat mammary tumour (OES HRI) has been grown in normal female rats
and in female and male rats supplemented with oestrone. In some rats, after the tumour was established, both
exogenous and endogenous sources of oestrogen were removed - a treatment which inhibited further growth
of the tumour. The proliferative characteristics of the tumours were measured by injecting the rats with
deoxybromouridine (BrdU) 4 h before removing the tumour. Extracted nuclei were reacted with anti-BrdU
and the labelling index and DNA content measured by flow cytometry. A correlation between the number of
(diploid) host cells present and the number of (aneuploid) tumour cells in S-phase of the cell cycle was
observed. This result suggests that there are paracrine interactions between tumour and host cells. We also
observed that, on oestrogen ablation, the labelling index was significantly reduced while the percentage of cells
in S-phase changed far less. The demonstration that there are cells in S-phase which are not proliferating
highlights a possible problem with the measurement of proliferation in human tumours from a DNA
histogram.
It has long been suspected that the growth of tumours is
influenced by their stromal environment. In particular, there
is growing evidence that paracrine interactions between
breast tumours and their stroma are important (Lipmann et
al., 1986; Osborne & Arteaga, 1990; and references therein)
and that stromal fibroblasts may play a key role. Much of
the supporting evidence for these statements is derived from
experiments in vitro, many of them using the human breast
carcinoma cell line, MCF7. An animal model in which
interactions between a breast tumour and its stroma can be
investigated could be of considerable value.
We have been studying the proliferative behaviour of an
oestrogen-sensitive rat tumour using labelling with
bromodeoxyuridine (BrdU) and flow cytometry (Smith et al.,
1991). This system has the advantage that the growth rate of
the tumour can be manipulated by altering the level of
oestrogen in the animal. Because normal (diploid) can be
distinguished from tumour (aneuploid) nuclei in a DNA
histogram, the labelling index can be measured and the
percentage of host nuclei can be quantified in the same
experiment. This tumour therefore offers a good model for
the study of stromal influences on tumour growth in vivo.
In this paper we report a correlation between the labelling
index of the tumour and the number of host cell nuclei.
The results also suggest that, in the absence of growth
stimuli, cells can stop proliferating in S-phase of the cell
cycle. This has implications for the estimation of prolifera-
tion by flow cytometry - a potentially useful prognostic
indicator in human breast cancer (for example, see O'Reilly
et al., 1989, 1990).
Experimental
Details of the tumours and the flow cytometric methods used
to study their proliferative capacity have been given
previously (Smith et al., 1991). The procedures are sum-
marised briefly below.
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Tumours
Pieces, 1 mm3 in size, of an oestrogen-sensitive mammary
tumour (OES HR1), developed from a tumour induced by
oestrone (Senior et al., 1985), were implanted in the flanks of
syngeneic CBH/CBi rats. Male rats (M +) and one group of
female rats (F +) were supplemented with oestrogen by
implanting a pellet of oestrone (15 mg/rat) and cholesterol
subcutaneously in the neck. Further experimental procedures
were commenced when the tumours were about 1.5 cm in
diameter. Tumours from groups M +, F + and F - (females
without oestrogen supplementation) were harvested. Oest-
rogen pellets were removed from rats in groups M + - and
F + -; ovariectomy being performed concomitantly on the
latter, and the tumours were harvested 10 days later. (See
Table I).
Determination ofBrdU labelling index
BrdU (100 mgkg') was injected into rats four hours before
tumour removal. After excision the tumours were ground to
a fine powder under liquid nitrogen and stored in this form
(this was to facilitate the determination of phosphorous-
containing metabolites in a separate parallel study; Smith et
al., 1991). The tissue powder was thawed in phosphate
buffered saline (PBS), repeatedly drawn up and down
through a pipette and filtered through 35 micron nylon mesh
to remove the connective tissue before the cells were fixed in
90% ethanol.
The procedure for labelling the nuclei was basically that of
Schutte et al. (1987) as described by McNally and Wilson
(1990). Nuclei were released by incubating the fixed cells in
pepsin (0.4 mgml-I in 0.1 MHCI) for 60 min at 37°C. After
Table I Nomenclature used to refer to the conditions ofgrowth ofthe
tumours
Code Sex Treatment
F- F None
F+ F Oestrogen supplement
F+- F Oestrogen supplement
Followed by oestrogen ablation
M+ M Oestrogen supplement
M+ - M Oestrogen supplement
Followed by oestrogen ablation
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filtration through 35 micron nylon mesh, the nuclei were
incubated in 2 MHCI at room temperature for 30 min,
washed in PBS and resuspended in 200 1l labelling solution
(PBS, 0.5% Tween-20, 0.5% foetal calf serum). Ten il rat
anti-BrdU monoclonal antibody (supernatant, ICR2
available commercially from Sera Labs Ltd., Crawley Down,
Sussex, England) was added and the nuclei incubated for
60min in the dark at room temperature. They were then
washed twice in PBS and incubated in labelling buffer with
goat anti-rat IgG fluorescein conjugate (Sera Labs) for a
further 60 min at room temperature. Finally, the nuclei were
washed twice and resuspended in PBS containing 10 lg ml-'
propidium iodide (PI).
Flow cytometry
The nuclei were analysed on an Ortho Cytofluorograf 50H
equipped with a Lexel argon-ion laser producing 50 mW at
488 nm and an Ortho 2150 computer system. After process-
ing to remove debris and clumped nuclei from the analysis
(see Ormerod, 1990), green (fluorescein -BrdU) versus red (PI
-DNA) fluorescence was recorded as a bivariate histogram
(cytogram) together with a separate univariate histogram of
red (DNA) fluorescence.
The labelling index was expressed as the percentage of
tumour cells which had taken up BrdU and was estimated
from the cytogram of BrdU versus DNA fluorescence. The
duration of S-phase was measured from the movement of
BrdU-labelled cells through the cell cycle in the four hours
between labelling with BrdU and removal of the tumour
(Begg et al., 1985).
The percentage of diploid cells was measured by gating on
the DNA histogram. The cell cycle parameters of the aneup-
loid (tumour) cells were computed (Ormerod et al., 1987)
after gating out the diploid cells.
Results
500 750 1000
G1% = 68.1
S% = 25.6
G2%= 6.3
250 500 750 1o00
Figure 2 A DNA histogram of a rat tumour grown in a female
supplemented with oestrogen. The upper part of the figure shows
the experimental histogram, the lower the result of the cycle
analysis on the aneuploid (tumour) cells with the percentages of
cells in the different phases of the cell cycle. Percentage diploid
(host) cells = 9%.
Figure 1 shows the histological appearance of the tumour. It
grew as islands of epithelial tumour cells surrounded by
stroma containing a high proportion of fibroblasts.
As previously reported (Smith et al., 1991), in the rats
supplemented with oestrogen, tumours grew faster in females
compared with males. In unsupplemented females, there was
an initial lag after which the growth rate was comparable
with the tumours grown with oestrogen supplementation. In
supplemented animals which underwent removal of oest-
rogen, there was no significant further increase in the size of
the tumours in the ten days following ablation.
Figure 2 shows a typical DNA histogram. The cell cycle
Figure 1 A photomicrograph of the rat mammary tumour -
OES HR1 - grown in a female rat.
components of the aneuploid tumour are marked. There is
also a diploid GI/GO peak from normal host cells in the
tumour sample.
Figure 3a shows a histogram of the percentage of cells
labelled with BrdU averaged for the groups F +, F + -,
M + and M + -. Oestrogen removal resulted in a significant
decrease in the number of cells actively synthesising DNA in
both the female and the male groups. For those cells that
were labelled, the transit time through S-phase showed only
small differences between the different groups. Figure 3b
shows the number of cells in S-phase, as measured from the
DNA histogram, averaged for the same animals in the same
four groups. Surprisingly, oestrogen removal did not result in
a significant change in the number of cells in S-phase.
Data from the groups F +, M + and F - (growing
tumours) and those from groups M + - and F + - (growth
arrested) were pooled. The number of cells in S-phase was
found to correlate significantly with the percentage of host
cells present for both sets of data (Figure 4).
Discussion
Validity ofthe data
The DNA histograms from the diploid normal and the
aneuploid tumour nuclei overlapped; the S- and G2M phases
from normal nuclei would have underlain the tumour histo-
gram and this would have affected the cell cycle analysis. In
human breast carcinomas, normal and tumour nuclei can
normally be separated on the basis of light scatter (Ormerod,
Imrie and Titley, submitted for publication) but this was not
possible with this particular rat tumour. The DNA index of
the tumour was 1.25 so that the peak from the normal G2M
would have fallen in the centre of S-phase (channel 550 in
Figure 2). There was no evidence ofa peak at this position inPROLIFERATION OF A RAT MAMMARY TUMOUR 109
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Figure 3 a, Histogram of the percentage of cells labelled with
BrdU averaged for the groups F +, F + -, M + and M + -. b,
Histogram of the percentage of tumour cells in S-phase of the cell
cycle averaged for the groups F +, F + -, M + and M + -.
any of the histograms suggesting that the normal G2M com-
ponent was relatively small.
Evidence from BrdU labelling showed that the number of
proliferating cells in host component was small (see Figure 2
in Smith et al., 1991). As the tumours grew, both the malig-
nant and the stromal cells must have increased together but,
because of the high rate of tumour cell loss observed in most
tumours (see, for example, Steel, 1977), a higher rate of
proliferation in the malignant cells is expected. It is unlikely
that the S-phase from normal cells significantly distorted the
results.
In summary, the evidence is that the correlations observed
in Figure 4 are genuine and not caused by an artifact of the
flow cytometric analysis.
Tumour-host relationships
We have observed a correlation between the number of host
cells and the percentage of tumour cells in S-phase (as
measured from the DNA histogram) in a hormone respon-
sive rat tumour model (Figure 4). There was a small differ-
ence between the correlation for growing tumours and that
for arrested tumours. This difference was not unexpected
since there were changes in the S-phase after oestrogen abla-
tion. These changes were smaller than expected (the signi-
ficance of this is discussed below) and the S-phase in these
tumours probably reflects the rate of proliferation prior to
oestrogen ablation.
The correlation suggests that the growth of cells within the
tumour mass is affected by interactions between malignant
cells and the surrounding stroma. From histological examina-
tion, it could be seen that the tumours were not heavily
infiltrated with lymphocytes or histiocytes; nodules of tumour
were embedded in a stroma rich in fibroblasts. It is therefore
possible (though far from proven) that the latter cell is
implicated.
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Figure 4 The percentage of tumour cells in S-phase plotted
against the percentage of host cells present. a, Groups F -, F +
and M + (growing tumours). b, Groups F + - and M + -
(arrested tumours).
There is good evidence for paracrine interactions between
fibroblasts and oestrogen-dependent breast carcinoma cells.
An influence of stromal fibroblasts on the growth of breast
carcinoma cells has been demonstrated in vivo (Gleiber &
Schiffman, 1984) and in vitro (Horgan et al., 1987; van
Roozendaal et al., 1992). There have been several accounts of
the production by fibroblasts of growth factors for breast
cells. For example, the production of IGF-1 by human
fibroblasts has been reported (Clemmons et al., 1981) and it
has been proposed that insulin-like growth factors, which act
synergistically with oestrogen on breast cells, are produced
by stromal cells (Yee et al., 1989; Van der Burg et al., 1990).
It has also been shown that human breast fibroblasts secrete
interleukin-6 which stimulates an increase of reductive E2
oxidoreductase (EOR) in a breast cancer cell line (MCF7)
(Adams et al., 1991). EOR converts oestrone to the more
biologically active 17 P-oestradiol. A gene which is expressed
specifically in stromal cells surrounding invasive breast car-
cinoma has also been identified (Basset et al., 1990).
The converse effect of the stimulation of fibroblasts by
factors produced by breast cells is also possible. Both plate-
let-derived growth factor and transforming growth factor-x -
growth factors which act on fibroblasts - are produced by
breast cancer cell lines (Rozengurt et al., 1985; Bronzert et
al., 1987; Peres et al., 1987; Bates et al., 1986, 1988) and the
production of such factors may be under hormonal control
(Dickson & Lipmann, 1987; Bates et al., 1986, 1988; Bronzert
et al., 1987).
It has been proposed that some anti-oestrogens may inhibit
the growth of breast tumours indirectly by affecting the
production of growth factors by stromal fibroblasts (Colletta
et al., 1990). Host-stromal interactions in breast cancer and
the affect of anti-tumour drugs thereon is clearly an impor-
tant area of study. Our results suggest that the OES HR1 rat
mammary tumour could be a useful model for such an
investigation.110 M.G. ORMEROD et al.
Measurement oftheproliferation in tumours
When solid tumours are labelled with BrdU in vivo, unlabel-
led cells in S-phase (as measured by their DNA content) are
always observed (Wilson et al., 1985); the same phenomenon
can be observed using 3H-thymidine and autoradiography of
sorted cells (Meyer et al., 1984). In this study, in tumours
grown with oestrogen supplementation, the percentage of
cells in S-phase was approximately 10% higher than the
labelling index. It is possible that the BrdU does not reach
some proliferating cells during the relatively short period of
labelling, due perhaps to transient changes in capillary flow
within the tumour. However, when animals were oestrogen
ablated, the discrepancy between the labelling index and the
S-phase increased dramatically. The reduced labelling index
was consistent with the observation that the tumours ceased
to grow after removal of oestrogen. The S-phase showed only
a small change - a result which shows that when a tumour
ceases to progress, cells can be completely or partially
arrested throughout the cell cycle. (If cells were progressing
very slowly through S-phase, they would take up little label
and would not be distinguished from unlabelled cells). This is
contrary to our experience in cell lines in vitro in which, upon
removal of an essential growth factor, cells progress around
the cycle to GI/GO before arresting.
The DNA histogram is the most convenient measure of
cell proliferation and the S-phase fraction is increasingly
being used as a prognostic indicator in human breast cancer.
Our results with the rat model show that the DNA histogram
can be misleading and suggest that data from human
tumours should be interpreted with caution, particularly in
tumours which have been treated with chemo- or endocrine
therapy. Ideally the proliferative characteristics of a tumour
should be measured by BrdU labelling but this is impractical
for use as a routine clinical measurement and several
laboratories are now searching for a reliable immunohis-
tochemical marker of proliferation. It is clear that a com-
parative study ofdifferent methods, including BrdU labelling,
needs to be made.
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